Navigation Links
Accera, Inc. to Present Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting

BROOMFIELD, Colo., April 24, 2007 /PRNewswire/ -- Accera Inc. announced today that topline data from its Phase IIb study of its lead compound AC-1202 in Alzheimer's disease (AD) will be presented at the annual meeting of the American Academy of Neurology (AAN) in Boston. Judged by the AAN to be in the top five percent of the program, the data will also be featured in the Scientific Highlights Plenary Session.

Accera's vice president of clinical development Dr. Lauren Costantini will present the abstract, "Clinical Efficacy of AC-1202 in Mild to Moderate Alzheimer's Disease" at the Late Breaking Science session on Tuesday, May 1 at 3:45 p.m. EDT. The plenary session will be held at 5:15 p.m. EDT on Friday, May 4.

The randomized, double-blinded, placebo-controlled Phase II trial evaluated 152 subjects that had previously been diagnosed with mild to moderate AD. Subjects visited the clinic on five occasions during the study to have their memory and other symptoms evaluated. Treatment lasted for three months and following a two-week washout, all subjects who had completed the three-month study were given the opportunity to participate in an open-label extension study. The open-label data will be presented at the Alzheimer's Association's International Prevention Conference in Washington, DC in early June.

About AC-1202

AC-1202 is an orally available, liquid compound that has been shown in preclinical studies to prevent the massive brain cell death seen in AD and other neurodegenerative diseases. Brain imaging techniques performed on AD patients reveal a decreased uptake of glucose, the brain's preferred source of energy. Efficiently converted by the liver into ketones, AC-1202 preserves the glucose-deprived brain cells with an alternative energy source. The potentially neuroprotective mechanism of AC-1202 is also being evaluated in age-associated memory impairment, Parkinson's disease, F
'"/>




Page: 1 2

Related medicine technology :

1. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
2. Accera, Inc. Announces Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
(Date:3/27/2015)... , March 27, 2015 XRpro ... for drug discovery and development services which features ... the pharmaceutical industry, announced financial results for the ... Timothy C.  Tyson, Chairman of XRpro Sciences commented, ... successfully transition from development stage to commercial stage ...
(Date:3/27/2015)... March 27, 2015 According to ... (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, ... Indication (AF, VT, WPW) - Global Forecasts to 2019 ", ... to reach around ~$4.73 Billion by 2019 with a ... to 2019. Browse   90   ...
(Date:3/27/2015)... , March 27, 2015  RXi Pharmaceuticals ... MirImmune LLC, today announced that they have ... RXi,s novel and proprietary sd-rxRNA® technology for ... The collaboration has the potential to result ... cancer treatments that could be a significant ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5
... Calif., May 18, 2011 Bayer HealthCare Pharmaceuticals, ... ONXX ) today announced results from a Phase ... with locally advanced or metastatic breast cancer previously ... Nexavar was associated with statistically significant improvements in ...
... SEATTLE, May 18, 2011 Dendreon Corporation (Nasdaq: ... poster presentation detailing clinical trial plans for PROVENGE® (sipuleucel-T) and ... upcoming American Society for Clinical Oncology annual meeting in Chicago, ... on Monday, June 6, 2011, from 8:00 a.m. to 12:00 ...
Cached Medicine Technology:Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 2Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 3Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 4Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 5Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 6Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 7Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 8Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 2Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 3Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 4
(Date:3/28/2015)... 28, 2015 Could genetic code determine ... study by researchers at the Harvard T.H. ... the support of the Coffee and Caffeine Genetics Consortium ... this past fall, the study—one of several recent HSPH ... data from more than 120,000 regular coffee drinkers of ...
(Date:3/28/2015)... 28, 2015 Take a bite of ... into action. Acids tumble into the stomach, ready to ... valve-like structure lets these acids run amok, triggering a ... common symptom. More than 60 million Americans have heartburn ... where heartburn starts, and how it can be stopped. ...
(Date:3/28/2015)... 28, 2015 Thousands of transvaginal ... by C.R. Bard, Inc. continue to move forward ... Court, Southern District of West Virginia, where Bernstein ... the Plaintiffs’ Steering Committee. According to an ... certain defendants named in those lawsuits leave to ...
(Date:3/28/2015)... 28, 2015 Emergency Medical Care (EMC), ... in Manhattan, recently commemorated its three-year anniversary of being ... In addition to 24-hour urgent care, Emergency Medical Care ... At this time, Emergency Medical Care’s Urgent Care ... chest pain, eye injuries, ear infections, fevers, insect bites, ...
(Date:3/28/2015)... 2015 An article in Fortune on ... prove critical to organizations that deal with PCI (Payment ... of data security, is worsening . Using numbers ... every major category out of the twelve measured improved, ... all the craziness that has gone on in the ...
Breaking Medicine News(10 mins):Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4
... News) -- Surgery can improve eye comfort and quality of ... their eyes, according to a small, new study. The ... for the cornea, which "can lead to exposure keratitis [inflammation ... wrote Dr. Douglas K. Henstrom, of Harvard Medical School and ...
... HealthDay Reporter , MONDAY, March 21 (HealthDay News) -- ... worst cases of potentially life-threatening blood clots that form in ... break loose and travel to the lungs, causing a pulmonary ... United States more than 250,000 people are hospitalized for deep ...
... HealthDay Reporter , MONDAY, March 21 (HealthDay News) ... gastric banding say they are generally satisfied years later, almost ... have to have their bands removed, a small, new Belgian ... a recent study out of the University of California, San ...
... new study published by researchers at Weill Cornell Medical ... in patient outcomes after a major earthquake through more ... hub to manage electronic traffic between first responders and ... injured victims will get timely care and survive, according ...
... March 21 (HealthDay News) -- People appear to be ... in a traffic crash than after other physically traumatic ... Gareth Jones, of the University of Aberdeen School of ... 2,069 people who provided information about musculoskeletal pain and ...
... patients in a federally funded study to determine if a ... "The question is, if you have kidney disease, should your ... of the GHSU Section of Nephrology and a principal investigator ... by the National Institutes of Health. The ...
Cached Medicine News:Health News:Severe Blood Clots Should be Treated Aggressively: Heart Docs 2Health News:Severe Blood Clots Should be Treated Aggressively: Heart Docs 3Health News:40% of Gastric Banding Patients Have Complications 2Health News:40% of Gastric Banding Patients Have Complications 3Health News:40% of Gastric Banding Patients Have Complications 4Health News:Health information technology 'control tower' could improve earthquake response 2Health News:Chronic Pain Often Follows Car Crash: Study 2Health News:Study examines whether lower blood pressure reduces kidney disease progression 2
For the quantitative determination of calcium in serum. Endpoint Reaction Product measured at 570 nm Linearity: 20 mg/dl...
Alanine Aminotransferase (ALT) reagent is used for the quantitative determination of alanine aminotransferase (Glutamate pyruvate transaminase, SGPT) in human serum....
... Intended for the quantitative determination ... serum or plasma. Two vials, ... tablets must be purchased separately ... Kinetic reaction. Wavelength: 340 nm. ...
... quantitative determination of alanine aminotransferase ... Single vial, dry powder reagent. ... purchased separately for conformity to ... 340 nm. Linearity: 440 U/L ...
Medicine Products: